Development of prime-boost-type next-generation mucosal vaccines

Area of Science:

• Immunology
• Vaccinology
• Microbiology

Background:

• Mucosal surfaces are primary entry points for pathogens.
• Current injectable vaccines poorly induce mucosal secretory IgA, limiting protection against mucosal pathogen invasion.
• Developing effective mucosal vaccines remains a significant challenge in infectious disease prevention.

Purpose of the Study:

• To develop and evaluate a novel parenteral vaccine formulation for inducing robust mucosal and systemic immune responses.
• To assess the vaccine's efficacy in preventing bacterial infections and ameliorating pathobiont-associated conditions.
• To explore the potential of this immunization strategy for treating infectious and non-infectious diseases.

Main Methods:

• Development of a parenteral vaccine using emulsified curdlan and CpG oligodeoxynucleotides.
• Immunization of animal models with specific bacterial antigens (Streptococcus pneumoniae, Clostridium ramosum).
• Evaluation of antigen-specific IgA induction at mucosal sites and systemic immunity.
• Assessment of protection against challenge infections and modulation of obesity in colonized mice.

Main Results:

• The novel vaccine successfully induced antigen-specific mucosal and systemic immune responses.
• High-titer IgA was recalled upon mucosal boosting, even after initial mucosal IgA waned.
• Vaccination with Streptococcus pneumoniae antigen conferred protection against lung infection.
• Clostridium ramosum vaccination reduced obesity in mice colonized with the microorganism.

Conclusions:

• This parenteral immunization strategy effectively induces protective mucosal immunity and systemic responses.
• The vaccine shows promise for preventing common infectious diseases and treating complex conditions like obesity and diabetes.
• This approach offers a potential new avenue for managing diseases mediated by intestinal bacteria.